Wolf, S. and Grössmann, N. (2020): Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble). Decision Support Document 123.

Wolf, S. and Grössmann, N. (2020): Home-Treatment in Child and Adolescent Psychiatry: An Analysis of the Effectiveness and Possible Implementation in Austria. HTA-Projektbericht 129.

Böhler, C.E.H. and Wolf, S. (2020): Lung Cancer Screening in Risk Groups: A Review-Update of the Economic Evidence (Part II). HTA-Projektbericht 132b.

Wolf, S. (2020): Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN). Update March 2022. Oncology Fact Sheet Nr. 28.

Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL). Withdrawal of the marketing authorisation in the European Union. Update November 2022. Oncology Fact Sheet Nr. 35.

Wolf, S. (2021): Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL). Update July 2021. Oncology Fact Sheet Nr. 38.

Wolf, S. (2021): Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC). Update March 2022. Oncology Fact Sheet Nr. 41.

Wolf, S. (2021): Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML). Update August 2021. Oncology Fact Sheet Nr. 47.

Wolf, S. (2021): Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC). Update August 2021. Oncology Fact Sheet Nr. 48.

Wolf, S. (2021): Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML). Update August 2021. Oncology Fact Sheet Nr. 49.

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma. Update August 2021. Oncology Fact Sheet Nr. 50.

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer. Update September 2021. Oncology Fact Sheet Nr. 51.

Wolf, S. (2021): Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC). Update September 2021. Oncology Fact Sheet Nr. 52.

Wolf, S. (2021): Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC). Update September 2021. Oncology Fact Sheet Nr. 53.

Wolf, S. (2021): Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapy for the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus. Update August 2021. Oncology Fact Sheet Nr. 54.

Wolf, S. (2021): Daratumumab (Darzalex®) in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (MM). Update September 2021. Oncology Fact Sheet Nr. 55.

Wolf, S. (2021): Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of newly diagnosed systemic light chain (AL) amyloidosis. Update September 2021. Oncology Fact Sheet Nr. 56.

Wolf, S. and Erdos, J (2021): Epidemiology of long COVID: a preliminary report. German short version of the original KCE report. HTA-Projektbericht 135a.

Grössmann, N. and Wolf, S. and Wild, C. (2021): Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD). Decision Support Document 127.

Wolf, S. and Strohmaier, C. (2021): Allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses. Decision Support Document 128.

Wolf, S. (2021): Idecabtagene vicleucel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM). Update September 2021. Oncology Fact Sheet Nr. 57.

Wolf, S. (2021): Tafasitamab (Minjuvi®; Monjuvi®) for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). Update November 2021. Oncology Fact Sheet Nr. 58.

Wolf, S. (2021): Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC). Update November 2021. Oncology Fact Sheet Nr. 59.

Wolf, S. (2021): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with Waldenström's Macroglobulinaemia (WM). Update February 2022. Oncology Fact Sheet Nr. 60.

Wolf, S. (2021): Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC). Update March 2022. Oncology Fact Sheet Nr. 61.

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma. Update February 2022. Oncology Fact Sheet Nr. 63.

Wolf, S. (2021): Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC). Update February 2022. Oncology Fact Sheet Nr. 64.

Wolf, S. and Erdos, J. (2021): Long COVID care pathways: a systematic review. HTA-Projektbericht 135b.

Wolf, S. (2021): Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC). Update January 2022. Oncology Fact Sheet Nr. 67.

Wolf, S. (2021): Pembrolizumab (Keytruda) in combination with Lenvatinib (Lenvima®) for the treatment of advanced or recurrent endometrial carcinoma (EC). Update February 2022. Oncology Fact Sheet Nr. 68.

Wolf, S. (2021): Amivantamab (Rybrevant®) as monotherapy for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations. Update March 2022. Oncology Fact Sheet Nr. 69.

Wolf, S. (2021): Sacituzumab govitecan (Trodelvy) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC). Update January 2022. Oncology Fact Sheet Nr. 70.

Wolf, S. (2022): Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer. Oncology Fact Sheet Nr. 72.

Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC). Update March 2022. Oncology Fact Sheet Nr. 74.

Wolf, S. (2022): Lorlatinib (Lorviqua®) as monotherapy for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC). Update March 2022. Oncology Fact Sheet Nr. 75.

Wolf, S. (2022): Tegafur/gimeracil/oteracil (Teysuno®) for the treatment of metastatic colorectal cancer. Update March 2022. Oncology Fact Sheet Nr. 76.

Rothschedl, E. and Wolf, S. (2022): Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer. Update June 2022. Oncology Fact Sheet Nr. 85.

Rothschedl, E. and Wolf, S. (2022): Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM). Update June 2022. Oncology Fact Sheet Nr. 86.

Rothschedl, E. and Wolf, S. (2022): Cabozantinib (Cabometyx®) as monotherapy for the treatment of locally advanced or metastatic differentiated thyroid carcinoma (DTC). Update June 2022. Oncology Fact Sheet Nr. 87.

Rothschedl, E. and Wolf, S. (2022): Tisagenlecleucel (Kymriah®) for the treatment of relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Update July 2022. Oncology Fact Sheet Nr. 88.

Rothschedl, E. and Wolf, S. (2022): Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL). Update July 2022. Oncology Fact Sheet Nr. 89.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the treatment of microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic colorectal cancer, advanced or recurrent endometrial carcinoma and unresectable or metastatic gastric, small intestine, or biliary cancer. Update July 2022. Oncology Fact Sheet Nr. 90.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for the treatment of persistent, recurrent, or metastatic cervical cancer. Update July 2022. Oncology Fact Sheet Nr. 91.

Rothschedl, E. and Wolf, S. (2021): Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST). Update May 2022. Oncology Fact Sheet Nr. 62.

Rothschedl, E. and Wolf, S. (2021): Sotorasib (Lumykras®): Sotorasib (Lumykras®) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation. Update May 2022. Oncology Fact Sheet Nr. 71.

Rothschedl, E. and Wolf, S. (2022): Lisocabtagene maraleucel (Breyanzi®) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). Update May 2022. Oncology Fact Sheet Nr. 77.

Rothschedl, E. and Wolf, S. (2022): Mosunetuzumab (Lunsumio®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL) Update September 2022. Oncology Fact Sheet Nr. 92.

Rothschedl, E. and Wolf, S. (2022): Capmatinib (Tabrecta®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Update October 2022. Oncology Fact Sheet Nr. 93.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) in combination with chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of locally advanced, or early‑stage triple‑negative breast cancer (TNBC). Update September 2022. Oncology Fact Sheet Nr. 94.

Rothschedl, E. and Wolf, S. (2022): Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced RET fusion positive non-small cell lung cancer (NSCLC). Update December 2022. Oncology Fact Sheet Nr. 95.

Rothschedl, E. and Wolf, S. (2022): Atezolizumab (Tecentriq®) as adjuvant treatment following complete resection and platinum-based chemotherapy for patients with non-small cell lung cancer (NSCLC). Update September 2022. Oncology Fact Sheet Nr. 96.

Rothschedl, E. and Wolf, S. (2022): Axicabtagene ciloleucel (Yescarta®) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). Update September 2022. Oncology Fact Sheet Nr. 97.

Rothschedl, E. and Wolf, S. (2022): Tepotinib (Tepmetko®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC). Update May 2022. Oncology Fact Sheet Nr. 73.

Rothschedl, E. and Wolf, S. (2022): Tebentafusp (Kimmtrak®) as monotherapy for the treatment of human leukocyte antigen (HLA) A*02:01 positive patients with unresectable or metastatic uveal melanoma. Update March 2023. Fact Sheet Nr. 79.

Rothschedl, E. and Wolf, S. (2022): Relugolix (Orgovyx®) for the treatment of advanced hormone-sensitive prostate cancer. Update November 2022. Oncology Fact Sheet Nr. 80.

Rothschedl, E. and Wolf, S. (2022): Selinexor (Nexpovio®) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma (MM). Update October 2022. Oncology Fact Sheet Nr. 98.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma who have undergone complete resection. Update October 2022. Oncology Fact Sheet Nr. 99.

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC). Update June 2022. Oncology Fact Sheet Nr. 81.

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Update June 2022. Oncology Fact Sheet Nr. 82.

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) in combination with chemotherapy for the first-line treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Update June 2022. Oncology Fact Sheet Nr. 83.

Rothschedl, E. and Wolf, S. (2022): Abemaciclib (Verzenios®) in combination with endocrine therapy for the adjuvant treatment of early breast cancer. Update June 2022. Oncology Fact Sheet Nr. 84.

Wolf, S. and Goetz, G. (2022): Subcutaneous implantable cardioverter-defibrillator (S-ICD). 1. Update 2022: Systematic review. Decision Support Document 109/ Update 2022.

Rothschedl, E. and Wolf, S. (2022): Melphalan flufenamide (Pepaxti®) with dexamethasone for the treatment of multiple myeloma (MM). Update October 2022. Oncology Fact Sheet Nr. 100.

Rothschedl, E. and Wolf, S. (2022): Asciminib (Scemblix®) for the treatment of Philadelphia chromosome‑positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP). Update November 2022. Oncology Fact Sheet Nr. 101.

Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer. Update November 2022. Oncology Fact Sheet Nr. 102.

Rothschedl, E. and Wolf, S. (2022): Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Update November 2022. Oncology Fact Sheet Nr. 103.

Rothschedl, E. and Wolf, S. (2022): Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer. Update December 2022. Oncology Fact Sheet Nr. 104.

Rothschedl, E. and Wolf, S. (2022): Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer. Oncology Fact Sheet Nr. 65.

Rothschedl, E. and Wolf, S. (2022): Degarelix (Firmagon®) for treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy. Oncology Fact Sheet Nr. 66.

Frühwirth, I. and Wolf, S. (2022): Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess individual breast cancer risk, their utility and applicability in a breast cancer screening programme. HTA-Projektbericht 145.

Rothschedl, E. and Wolf, S. (2023): Olaparib (Lynparza®) in combination with abiraterone and prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update April 2023. Oncology Fact Sheet Nr. 117.

Rothschedl, E. and Wolf, S. (2022): Relatlimab/nivolumab (Opdualag®) for the first line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%. Update December 2022. Oncology Fact Sheet Nr. 105.

Rothschedl, E. and Wolf, S. (2022): Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Update December 2022. Oncology Fact Sheet Nr. 106.

Rothschedl, E. and Wolf, S. (2022): Teclistamab (Tecvayli®) as monotherapy for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies. Update December 2022. Oncology Fact Sheet Nr. 107.

Rothschedl, E. and Wolf, S. (2022): Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC). Update March 2023. Fact Sheet Nr. 108.

Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Update September 2022. Oncology Fact Sheet Nr. 16.

Rothschedl, E. and Wolf, S. (2022): Avapritinib (Ayvakyt®) for the treatment of advanced systemic mastocytosis (AdvSM). Update September 2022. Oncology Fact Sheet Nr. 78.

Wolf, S. (2022): Long COVID care pathways and structures: an updated scoping review. HTA-Projektbericht 135b/ Update.

Rothschedl, E. and Wolf, S. (2022): Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Update July 2023. Fact Sheet Nr. 109.

Rothschedl, E. and Wolf, S. (2022): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of marginal zone lymphoma (MZL). Update March 2023. Fact Sheet Nr. 110.

Rothschedl, E. and Wolf, S. (2022): Axicabtagene ciloleucel (Yescarta®) for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Update March 2023. Fact Sheet Nr. 111.

Rothschedl, E. and Wolf, S. (2022): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL). Update March 2023. Fact Sheet Nr. 112.

Rothschedl, E. and Wolf, S. (2022): Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer. Update March 2023. Fact Sheet Nr. 113.

Rothschedl, E. and Wolf, S. (2022): Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update April 2023. Oncology Fact Sheet Nr. 114.

Rothschedl, E. and Wolf, S. (2021): Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM). Update November 2022. Oncology Fact Sheet Nr. 39.

Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. Update April 2023. Oncology Fact Sheet Nr. 115.

Rothschedl, E. and Wolf, S. (2022): Durvalumab (Imfinzi®) in combination with gemcitabine and cisplatin for the first‑line treatment of unresectable or metastatic biliary tract cancer (BTC). Update April 2023. Oncology Fact Sheet Nr. 116.

Rothschedl, E. and Wolf, S. (2023): Tremelimumab (Imjudo®) in combination with durvalumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Update July 2023. Oncology Fact Sheet Nr. 118.

Rothschedl, E. and Wolf, S. (2023): Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). Update April 2023. Oncology Fact Sheet Nr. 119.

Rothschedl, E. and Wolf, S. (2023): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer. Update April 2023. Oncology Fact Sheet Nr. 120.

Rothschedl, E. and Wolf, S. (2023): Nadofaragene firadenovec (Adstiladrin®) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours. Update June 2023. Fact Sheet Nr. 121.

Rothschedl, E. and Wolf, S. (2023): Oportuzumab monatox for the treatment of noninvasive urothelial carcinoma in situ (CIS) previously treated with Bacillus Calmette-Guérin (BCG). Update June 2023. Fact Sheet Nr. 122.

Rothschedl, E. and Wolf, S. (2023): Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone‑sensitive prostate cancer (mHSPC). Update June 2023. Fact Sheet Nr. 123.

Rothschedl, E. and Wolf, S. (2023): Niraparib/abiraterone acetate (Akeega®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update July 2023. Fact Sheet Nr. 125.

Rothschedl, E. and Wolf, S. (2023): Ivosidenib (Tibsovo®, Tidhesco® ) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML). Update June 2023. Fact Sheet Nr. 126.

Rothschedl, E. and Wolf, S. (2023): Cemiplimab (Libtayo®) in combination with platinum‐based chemotherapy for the first‐line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Update June 2023. Fact Sheet Nr. 128.

Rothschedl, E. and Wolf, S. (2023): Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). Update July 2023. Fact Sheet Nr. 129.

Rothschedl, E. and Wolf, S. (2023): Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma. Update July 2023. Fact Sheet Nr. 132.

Rothschedl, E. and Wolf, S. (2023): Nivolumab (Opdivo®) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC). Update October 2023. Fact Sheet Nr. 133.

Rothschedl, E. and Wolf, S. (2023): Piflufolastat (18F) (Pylclari®) for the diagnosis of prostate cancer. Update October 2023. Fact Sheet Nr. 134.

Wolf, S. and Al Froukh, R.F. (2023): 177Lu-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Systematic Review. 1st Update 2023. Decision Support Document 118/ Update 2023.

Wolf, S. and Reinsperger, I. (2023): Strategies for recruitment and programme adherence in group programmes for children, adolescents and adults with overweight and grade 1 obesity. HTA-Projektbericht 155.

Jeindl, R. and Wolf, S. (2024): Calcitonin gene-related peptide antagonists for the prevention of migraine - summary of the BAG /RACS HTA report 2023. Rapid Review Nr.: 011.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018. HSO: 35th Prioritisation.

Wolf, S. and Grössmann, N. (2017): Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer. DSD: Horizon Scanning in Oncology 65.

Grössmann, N. and Wolf, S. (2017): Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy. DSD: Horizon Scanning in Oncology 66.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 33rd Prioritisation – 4th quarter 2017. HSO: 33rd Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 39th Prioritisation – 2nd quarter 2019 . HSO: 39th Prioritisation.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 30th Prioritisation – 1st quarter 2017. HSO: 30th Prioritisation.

Stanak, M. and Wolf, S. and Jagoš, H. (2018): External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine. Decision Support Document 114.

Grössmann, N. and Wolf, S. and Rothschedl, E. (2019): Horizon Scanning in Oncology 38th Prioritisation – 1st quarter 2019. HSO: 38th Prioritisation.

Fuchs, E. and Wolf, S. and Scrozynski, G. (2019): Cervical Carcinoma Prevention - Implementation of an HPV screening test for early detection of cervical cancer in Austria . HTA-Projektbericht 121.

Wolf, S. and Wild, C. (2018): Drug reimbursement in the inpatient sector in Austria: Approaches for a transparent and evidence-based process, taking into account international experience . HTA-Projektbericht 109.

Scarfe, A. and Wolf, S. (2019): Human dermal allograft for massive rotator cuff tears. Decision Support Document 117.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 41st Prioritisation – 4th quarter 2019. HSO: 41st Prioritisation.

Wolf, S. and Rosian, K. (2019): Single/two-step scaffold-based cartilage repair in the knee and ankle joint . Decision Support Document 98/ Update 2019.

Wolf, S. (2017): Ipilimumab (Yervoy®) in the adjuvant therapy for high-risk stage III cutaneous melanoma. DSD: Horizon Scanning in Oncology 67.

Wolf, S. and Fischer, S. (2017): Transcatheter Aortic Valve Implantation Part I: A systematic review of health economic evaluations. HTA-Projektbericht 95a.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 37th Prioritization – 4th quarter 2018. HSO: 37th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 40th Prioritisation – 3rd quarter 2019. HSO: 40th Prioritisation.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 32nd Prioritisation – 3rd quarter 2017. HSO: 32nd Prioritisation.

Wolf, S. and Winkler, R. (2019): Rehabilitation for children and adolescents in Austria: A systematic analysis of evaluation methodologies. HTA-Projektbericht 122.

Grössmann, N. and Wolf, S. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 29th Prioritisation – 4th quarter 2016.. HSO: 29th Prioritisation.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 31st Prioritisation – 2nd quarter 2017 . HSO: 31st Prioritisation.

Grössmann, N. and Wolf, S. (2018): Horizon Scanning in Oncology 34th Prioritisation – 1st quarter 2018. HSO: 34th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 36th Prioritisation – 3rd quarter 2018. HSO: 36th Prioritisation.

Wolf, S. and Stanak, M. (2018): Allogeneic mesenchymal stem cells for Crohn’s disease-associated complex perianal fistulas. Decision Support Document 111.